Physician profile

Anna M Haring

Obstetrics & Gynecology · Edmonds, WA

NPI 1104231018

$2,158.75

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$24.67

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Olympus Corporation of The Americas $1,840.69 2019
Abbvie INC. $89.04 2019-2021
Merck Sharp & Dohme LLC $66.34 2019-2021
Bayer Healthcare Pharmaceuticals INC. $57.69 2020-2022
Hologic Sales and Service, LLC $24.67 2024 Acessa Provu System
Novo Nordisk INC $22.37 2019
Organon LLC $19.53 2021
Amgen INC. $15.35 2021
Daiichi Sankyo INC. $11.94 2019
Pfizer INC. $11.13 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anna M Haring

$2,158.75

in general payments reported 2019-2025

Years
2019-2024
Top company
Olympus Corporation of The Americas

https://glasscript.com/doctor/565175/anna-m-haring

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.